Literature DB >> 3026696

A canine model of induced purine nucleoside phosphorylase deficiency.

W R Osborne, H J Deeg, S J Slichter.   

Abstract

Purine nucleoside phosphorylase (NP EC 2.4.2.1) deficiency in man is associated with selective T cell dysfunction and normal B cell immunity. To create an in-vivo model of this immune deficiency, we administered 8-aminoguanosine to dogs. This water soluble nucleoside was rapidly converted by NP to the more potent product inhibitor 8-aminoguanine, which had a Ki of 0.52 microM. The accumulation of inosine and exogenous deoxyguanosine in plasma provided evidence that administration of 8-aminoguanosine was effectively inhibiting NP activity. Four dogs given 8-aminoguanosine and deoxyguanosine concurrently for 5 consecutive days showed mean reductions in peripheral blood lymphocytes of 65 +/- 9% range (55-75%) over the test period. Granulocytes, red blood cells, and plateletes remained within the normal range. Administration of 8-aminoguanosine to dogs provides a model of NP deficiency that will permit studies of the specific control of lymphopoiesis and in-vivo immune function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026696      PMCID: PMC1542671     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Purine metabolism in primitive erythrocytes.

Authors:  R E Parks; P R Brown; Y C Cheng; K C Agarwal; C M Kong; R P Agarwal; C C Parks
Journal:  Comp Biochem Physiol B       Date:  1973-06-15

2.  Rapid determination of nucleoside kinase and nucleotidase activities with tritium-labeled substrates.

Authors:  D H Ives; J P Durham; V S Tucker
Journal:  Anal Biochem       Date:  1969-04-04       Impact factor: 3.365

3.  A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts.

Authors:  C Garrett; D V Santi
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

4.  Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species.

Authors:  K C Agarwal; R P Agarwal; J D Stoeckler; R E Parks
Journal:  Biochemistry       Date:  1975-01-14       Impact factor: 3.162

5.  Purine nucleoside phosphorylase deficiency. Measurement of variant protein in four families with enzyme-deficient members by an enzyme-linked immunosorbent assay.

Authors:  W R Osborne; C R Scott
Journal:  Am J Hum Genet       Date:  1980-11       Impact factor: 11.025

6.  Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.

Authors:  I S Kazmers; B S Mitchell; P E Dadonna; L L Wotring; L B Townsend; W N Kelley
Journal:  Science       Date:  1981-12-04       Impact factor: 47.728

7.  Inhibitors of purine nucleoside phosphorylase, C(8) and C(5') substitutions.

Authors:  J D Stoeckler; C Cambor; V Kuhns; S H Chu; R E Parks
Journal:  Biochem Pharmacol       Date:  1982-01-15       Impact factor: 5.858

8.  Canine cyclic hematopoiesis is associated with abnormal purine and pyrimidine metabolism.

Authors:  W R Osborne; W P Hammond; D C Dale
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

10.  PURINE NUCLEOSIDES. IX. THE SYNTHESIS OF 9-BETA-D-RIBOFURANOSYL URIC ACID AND OTHER RELATED 8-SUBSTITUTED PURINE RIBONUCLEOSIDES.

Authors:  R E HOLMES; R K ROBINS
Journal:  J Am Chem Soc       Date:  1965-04-20       Impact factor: 15.419

View more
  1 in total

1.  Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans.

Authors:  W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.